Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma

Oncogenesis

Volumn 4, Issue 7, 2015, Pages

  Lefevre L ^a,b,c   Omeiri, H ^a,b,c   Drougat, L ^a,b,c   Hantel, C ^d   Giraud, M ^a,b,c   Val, P ^b,e,f   Rodriguez, S ^a,b,c   Perlemoine, K ^a,b,c   Blugeon, C ^a,b,g   Beuschlein, F ^d   De Reynies A ^h   Rizk Rabin, M ^a,b,c   Bertherat, J ^a,b,c,i   Ragazzon, B ^a,b,c  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f Faculté de Médecine   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h Cartes d'Identité des Tumeurs Program Ligue Nationale Contre le Cancer   (France)

ⁱ Ligue Nationale Contre le Cancer ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; RNA; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX CELL; AFF3 GENE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA SPLICING; TRANSCRIPTION INITIATION SITE; TRANSCRIPTOMICS;

EID: 84989336964     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.20     Document Type: Article

References (49)

1. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14: 13-28.
2. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197.
3. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810.
4. Holland JD, Klaus A, Garratt AN, Birchmeier W. Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol 2013; 25: 254-264.
5. Kuhl SJ, Kuhl M. On the role of Wnt/beta-catenin signaling in stem cells. Biochim Biophys Acta 2013; 1830: 2297-2306.
6. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-1205.
7. Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development 2008; 135: 2593-2602.
8. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 2014; 46: 607-612.
9. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet 2010; 19: 1561-1576.
10. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ et al. Progression to adrenocortical tumorigenesis in mice and humans through insulinlike growth factor 2 and beta-catenin. Am J Pathol 2012; 181: 1017-1033.
11. Doghman M, Cazareth J, Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab 2008; 93: 3222-3225.
12. Gaujoux S, Hantel C, Launay P, Bonnet S, Perlemoine K, Lefevre L et al. Silencing mutated beta-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS ONE 2013; 8: e55743.
13. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010; 70: 8276-8281.
14. Metsu S, Rooms L, Rainger J, Taylor MS, Bengani H, Wilson DI et al. FRA2A is a CGG repeat expansion associated with silencing of AFF3. PLoS Genet 2014; 10: e1004242.
15. Melko M, Douguet D, Bensaid M, Zongaro S, Verheggen C, Gecz J et al. Functional characterization of the AFF (AF4/FMR2) family of RNA-binding proteins: insights into the molecular pathology of FRAXE intellectual disability. Hum Mol Genet 2011; 20: 1873-1885.
16. Luo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, Swanson S et al. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Mol Cell Biol 2012; 32: 2608-2617.
17. Thakur R, Mishra DP. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 2013; 17: 449-456.
18. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005; 65: 7622-7627.
19. Gaujoux S, Tissier F, Groussin L, Libe R, Ragazzon B, Launay P et al. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab 2008; 93: 4135-4140.
20. Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) 2008; 68: 264-270.
21. Kim A, Giordano TJ, Kuick R, Serecky K, Hammer GD. Wnt/betacatenin signaling in adrenocortical stem/progenitor cells: implications for adrenocortical carcinoma. Ann Endocrinol (Paris) 2009; 70: 156.
22. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R et al. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011; 17: 328-336.
23. Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B et al. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-Activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and-nonsecreting tumors. J Clin Endocrinol Metab 2011; 96: E419-E426.
24. von Bergh AR, Beverloo HB, Rombout P, van Wering ER, van Weel MH, Beverstock GC et al. LAF4, an AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia. Genes Chromosomes Cancer 2002; 35: 92-96.
25. Hiwatari M, Taki T, Taketani T, Taniwaki M, Sugita K, Okuya M et al. Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t (2;11)(q11;q23). Oncogene 2003; 22: 2851-2855.
26. Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev 2011; 25: 661-672.
27. Britanova O, Lukyanov S, Gruss P, Tarabykin V. The mouse Laf4 gene: exon/intron organization, cDNA sequence, alternative splicing, and expression during central nervous system development. Genomics 2002; 80: 31-37.
28. Steichen-Gersdorf E, Gassner I, Superti-Furga A, Ullmann R, Stricker S, Klopocki E et al. Triangular tibia with fibular aplasia associated with a microdeletion on 2q11.2 encompassing LAF4. Clin Genet 2008; 74: 560-565.
29. Moore JM, Oliver PL, Finelli MJ, Lee S, Lickiss T, Molnar Z et al. Laf4/Aff3, a gene involved in intellectual disability, is required for cellular migration in the mouse cerebral cortex. PLoS One 2014; 9: e105933.
30. Barton A, Eyre S, Ke X, Hinks A, Bowes J, Flynn E et al. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-Autoimmune susceptibility genes. Hum Mol Genet 2009; 18: 2518-2522.
31. Plant D, Flynn E, Mbarek H, Dieude P, Cornelis F, Arlestig L et al. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis 2010; 69: 1548-1553.
32. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP et al. Genomewide association study meta-Analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508-514.
33. Freudenberg J, Lee HS, Han BG, Shin HD, Kang YM, Sung YK et al. Genome-wide association study of rheumatoid arthritis in Koreans: population-specific loci as well as overlap with European susceptibility loci. Arthritis Rheum 2011; 63: 884-893.
34. Wallace C, Rotival M, Cooper JD, Rice CM, Yang JH, McNeill M et al. Statistical colocalization of monocyte gene expression and genetic risk variants for type 1 diabetes. Hum Mol Genet 2012; 21: 2815-2824.
35. Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012; 8: e1002921.
36. Ploski R, Szymanski K, Bednarczuk T. The genetic basis of graves' disease. Curr Genomics 2011; 12: 542-563.
37. To MD, Faseruk SA, Gokgoz N, Pinnaduwage D, Done SJ, Andrulis IL. LAF-4 is aberrantly expressed in human breast cancer. Int J Cancer 2005; 115: 568-574.
38. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000; 97: 4262-4266.
39. Spector DL, Lamond AI. Nuclear speckles. Cold Spring Harb Perspect Biol 2011; 3.
40. Giraud M, Jmari N, Du L, Carallis F, Nieland TJ, Perez-Campo FM et al. An RNAi screen for Aire cofactors reveals a role for Hnrnpl in polymerase release and Aire-Activated ectopic transcription. Proc Natl Acad Sci USA 2014; 111: 1491-1496.
41. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-533.
42. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
43. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
44. Groussin L, Massias JF, Bertagna X, Bertherat J. Loss of expression of the ubiquitous transcription factor cAMP response element-binding protein (CREB) and compensatory overexpression of the activator CREMtau in the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2000; 85: 345-354.
45. Ragazzon B, Cazabat L, Rizk-Rabin M, Assie G, Groussin L, Fierrard H et al. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1 A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res 2009; 69: 7278-7284.
46. Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 2013; 369: 2105-2114.
47. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol 2007; 21: 2968-2987.
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
49. Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 2006; 224: 213-232.